PDCD1 and neoplasm: While TSCs have been used to evaluate the effects of chemotherapy agents in primary tumor specimens [8–10], only a limited number of recent studies have leveraged them to determine the consequences of immunotherapies such as anti-PD-1, anti-TIM-3, anti-IL-10 and CAR-T cells [11, 12].